Study Finds Common Joint Supplement May Accelerate Alzheimer’s Progression

A recent analysis of health records spanning millions of patients has identified a possible link between the widely‑taken joint supplement glucosamine and a faster transition from mild cognitive impairment to dementia, raising new concerns about the supplement’s safety profile.

The observational study, which examined prescription and over‑the‑counter use of glucosamine among individuals diagnosed with mild cognitive impairment, found that those who regularly reported taking the supplement were about 25 percent more likely to develop Alzheimer’s‑type dementia over the follow‑up period than non‑users, after adjusting for age, gender, cardiovascular risk factors and other common medications.

Complementary laboratory work reported alongside the epidemiological findings suggests that glucosamine may amplify a pathological process known as O‑GlcNAcylation, an abnormal attachment of sugar molecules to neuronal proteins that has been implicated in the formation of toxic amyloid plaques and tau tangles characteristic of Alzheimer’s disease.

Glucosamine, derived from shellfish exoskeletons or produced synthetically, is one of the best‑selling dietary supplements for osteoarthritis and joint pain, with sales exceeding billions of dollars annually in the United States and Europe. Until now, it has been regarded as low‑risk, with few serious adverse events reported in clinical trials focused on joint health.

The new findings do not establish a causal relationship, but they prompt clinicians and consumers to weigh potential cognitive risks against joint‑health benefits. Researchers plan to conduct prospective trials to confirm the association and to explore whether dosage, formulation or duration of use influence the observed effect. In the meantime, health professionals are advised to discuss the emerging evidence with patients who have existing memory concerns and to monitor cognitive changes in glucosamine users.